TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Theravance Biopharma ( (TBPH) ) has provided an announcement.
On June 26, 2025, Theravance Biopharma announced that Viatris secured regulatory approval from China’s NMPA for YUPELRI® (revefenacin) inhalation solution, marking it as the first once-daily nebulized LAMA for COPD maintenance treatment in China. This approval triggers a $7.5 million milestone payment from Viatris to Theravance, expected in Q3 2025, and positions Theravance for further sales-based milestones and royalties, enhancing its financial standing without incurring commercial costs in China.
The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.
Spark’s Take on TBPH Stock
According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.
Theravance Biopharma’s stock score reflects a mix of financial stabilization and positive technical momentum, offset by valuation concerns due to unprofitability. The company shows potential for growth with improved cash flow and strategic advancements, but profitability and valuation issues need addressing.
To see Spark’s full report on TBPH stock, click here.
More about Theravance Biopharma
Theravance Biopharma, Inc. is a company focused on delivering impactful medicines, leveraging decades of expertise. It has developed FDA-approved YUPELRI® for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and is advancing ampreloxetine, a late-stage investigational treatment for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy.
Average Trading Volume: 280,160
Technical Sentiment Signal: Buy
Current Market Cap: $529M
For a thorough assessment of TBPH stock, go to TipRanks’ Stock Analysis page.